EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics

Mingyao Huang, Fang Wei, Jilong Cao, Hongzhou Jiang

Bioorganic Chemistry · 2025-10 · 165 · 108985

DOI: 10.1016/j.bioorg.2025.108985 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025-10. Verfasst von Mingyao Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Putian University, Putian 351100, Fujian, PR China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 160 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer remains one of the deadliest malignancies, with limited therapeutic options and a dismal prognosis. Traditional treatment modalities, including chemotherapy and molecular targeted therapies, often face challenges such as drug resistance, limited targetability, and systemic toxicity. The emergence of proteolysis-targeting chimeras (PROTACs) has opened a new frontier in targeted protein degradation, offering a promising approach to overcome these limitations by hijacking the ubiquitin-proteasome system to selectively degrade disease-related proteins. This review provides a comprehensive overview of the design principles and molecular components of PROTACs, including POI ligands, E3 ligase ligands, and linker strategies. We further highlight recent progress in the application of PROTACs in pancreatic cancer therapy, focusing on their ability to target oncogenic kinases, epigenetic regulators, antiapoptotic proteins, metabolic regulators, and transcription factors. Despite significant advances, the clinical translation of PROTACs faces multiple challenges, including poor cell permeability, off-target effects, tissue toxicity, and acquired resistance. Finally, we discuss future perspectives on rational design, tissue-specific delivery systems, and combination strategies to fully realize the therapeutic potential of PROTACs in pancreatic cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPancreatic NeoplasmsProteolysis Targeting ChimeraAnimalsHumansMolecular StructureProteolysis

Stichwörter der Autor:innen

Cancer therapeuticsE3 ligasePROTACsPancreatic cancerTargeted protein degradation

Substanzen

Antineoplastic AgentsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • School of Basic Medicine, Putian University, Putian 351100, Fujian, PR China.
  • Department of General surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang 110000, Liaoning Province, PR China.
  • Department of Health Management, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, PR China. Electronic address: jlcao@cmu.edu.cn.
  • Department of Neurosurgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, PR China. Electronic address: jianghongzhous@126.com.

Zitieren

APA

Huang, M., Wei, F., Cao, J., & Jiang, H. (2025). Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics. Bioorganic Chemistry, 165, 108985. https://doi.org/10.1016/j.bioorg.2025.108985

Vancouver

Huang M, Wei F, Cao J, Jiang H. Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics. Bioorganic Chemistry. 2025;165:108985. doi:10.1016/j.bioorg.2025.108985

BibTeX
@article{Huang2025,
  author = {Huang, Mingyao and Wei, Fang and Cao, Jilong and Jiang, Hongzhou},
  title = {Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics},
  journal = {Bioorganic Chemistry},
  year = {2025},
  volume = {165},
  pages = {108985},
  doi = {10.1016/j.bioorg.2025.108985}
}
Kostenlos starten →